XML 52 R32.htm IDEA: XBRL DOCUMENT
v3.19.1

COMMERCIALIZATION AGREEMENTS (Narrative) (Details) - USD ($) $ in Millions | 1 Months Ended |
--- | --- | ---
Jul. 23, 2018 | Oct. 19, 2017 | Oct. 31, 2015 | Nov. 30, 2009
Protalix Bio Therapeutics Incorporation [Member] |  |  |  |
Collaborative Arrangement Profit Share Percentage |  |  |  | 40.00%
Pfizer [Member] |  |  |  |
Stock Issued During Period, Shares, New Issues |  |  | 5,649,079 |
Debt Instrument, Face Amount |  |  | $ 4.3 |
Chiesi US Agreement [Member] |  |  |  |
Upfront Nonrefundable Noncreditable Payment Receivable | $ 25.0 | $ 25.0 |  |
Additional Amounts Payable To Cover Development Costs | 20.0 |  |  |
Maximum Entitlement Of Development Costs To Cover Per Year | 7.5 |  |  |
Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones | $ 760.0 |  |  |
Chiesi US Agreement [Member] | Maximum [Member] |  |  |  |
Payment On Net Sales Percentage | 40.00% |  |  |
Chiesi US Agreement [Member] | Minimum [Member] |  |  |  |
Payment On Net Sales Percentage | 15.00% |  |  |
Chiesi Ex US Agreement [Member] |  |  |  |
Upfront Nonrefundable Noncreditable Payment Receivable |  | 25.0 |  |
Additional Amounts Payable To Cover Development Costs |  | 25.0 |  |
Maximum Entitlement Of Development Costs To Cover Per Year |  | 10.0 |  |
Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones |  | $ 320.0 |  |
Chiesi Ex US Agreement [Member] | Maximum [Member] |  |  |  |
Payment On Net Sales Percentage |  | 35.00% |  |
Chiesi Ex US Agreement [Member] | Minimum [Member] |  |  |  |
Payment On Net Sales Percentage |  | 15.00% |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The definition should be: "The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement profit sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |